Fosun Pharma subsidiary advances drug clinical trial

Shanghai Fosun Pharmaceutical (Group) Co.'s subsidiary is progressing with clinical trials for its innovative drug, Luvometinib, a MEK1/2 selective inhibitor. The Phase III clinical trial will assess the drug's effectiveness in treating children with low-grade glioma in China, excluding Hong Kong, Macau, and Taiwan. The drug already has approval for marketing in China for certain conditions. As of May 2025, the company has invested approximately RMB607 million in the drug's research and development. The company highlighted potential risks inherent in drug development, including trial terminations.